The tau pathway is the focus of a new investment by Bristol-Myers Squibb Company which is planning to spend $175 million in cash and potential milestones of $550 million to acquire the privately-owned biotechnology company iPierian Inc.
Zealand Pharma A/S, a Danish producer of peptide drugs, had a profit of DKK 28.8 million in the first 2014 quarter compared with a loss of DKK 57.3 million a year earlier.
GlaxoSmithKline Plc faced strong competition to its respiratory franchise in the US in the first quarter with the result that group sales declined by 2% at constant exchange rates and the company’s core operating profit was flat.
Silence Therapeutics Plc, a UK company exploring potential therapeutics based on RNA interference, has raised £11.4 million in a private equity placement with institutional investors and management to support its ongoing research and development activities.
Sanofi SA continued its momentum towards a recovery of sales and stronger earnings in the first quarter as most of its diversified portfolio showed year-on-year revenue gains measured in constant currencies.
MorphoSys AG is set to install its latest antibody discovery technology at a unit of Temple University in Philadelphia, Pennsylvania, US as part of an alliance aimed at identifying new antibodies f
Pfizer Inc’s potential bid for AstraZeneca Plc appeared to be gaining traction following a Pfizer conference with analysts on 28 April and a formal declaration of interest to the London Stock Exchange earlier the same day.
AstraZeneca Plc has issued a statement saying that in the absence of a “specific and attractive proposal” from Pfizer Inc to merge, it would be inappropriate to engage in discussions on the matter.
In a statement to the London Stock Exchange on 28 April, Pfizer Inc confirmed that it has approached AstraZeneca Plc twice about a possible merger, and remains interested in a transaction should this be unanimously recommended by AstraZeneca’s directors.
About 4,000 trials are ongoing in cell-based technology – of which an estimated 1,058 are novel treatments. The cell therapy industry would be transformed if just 100 of these novel treatments successfully completed clinical development and reached the market.